Company Overview
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury.
Latest Presentation
Upcoming Event
Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference
Latest Financial Results

Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
Email Alerts
Receive updates straight into your inbox
Stock Inforamtion
IR Contacts
Company
Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com
Investor Relations
T: 650-543-5470
ir@unicycive.com
Transfer Agent
Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003